Wendy T Parker

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease

Susan Branford, Paul Wang, David T Yeung et al. · Blood · 2018 · 209 citations · Full text

Medicine, Genetics, Molecular Genetics +12

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

Susan Branford, David T Yeung, Wendy T Parker et al. · Blood · 2014 · 198 citations

Medicine, Hematology, Oncology +8

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Michael W. Deininger, John Hodgson, Neil P. Shah et al. · Blood · 2015 · 105 citations · Full text

Medicine, Oncology, Pharmacology +10

A comparative analysis of algorithms for somatic SNV detection in cancer

Nicola D. Roberts, R. Daniel Kortschak, Wendy T Parker et al. · Bioinformatics · 2013 · 98 citations · Full text

Life Sciences, Genetics, Oncology +17

Sensitive Detection of <i>BCR-ABL1</i> Mutations in Patients With Chronic Myeloid Leukemia After Imatinib Resistance Is Predictive of Outcome During Subsequent Therapy

Wendy T Parker, Rebecca Lawrence, Musei Ho et al. · Journal of Clinical Oncology · 2011 · 96 citations · Full text

Medicine, Hematology, Oncology +17